News
Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...
Alpha-1 antitrypsin deficiency (AATD), bronchoscopic lung volume reduction (BLVR), COPD, emphysema, endobronchial valves, hyperinflation, interventional pulmonology, lung volume reduction therapy.
The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added ...
The North America alpha-1 antitrypsin deficiency market is expected to lead globally due to advanced healthcare infrastructure, high awareness, and significant research investments. The market is ...
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies, GlaxoSmithKline, AstraZeneca, Merck, Pfizer ...
AIRNA’s lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen ...
Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity. This ...
(RTTNews) - Beam Therapeutics Inc. (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...
About Alpha-1 Antitrypsin Deficiency (AATD) AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease.
The AATD program aims to develop a treatment for alpha-1 antitrypsin deficiency using Prime Editing technology. When does Prime Medicine expect to file for clinical trials?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results